Dual targeting of vascular endothelial growth factor and bone morphogenetic protein‐9/10 impairs tumor growth through inhibition of angiogenesis

Clinical development of anti‐angiogenic agents has been a major landmark in cancer therapy for several types of cancers. Signals mediated by both vascular endothelial growth factor (VEGF) and bone morphogenetic protein (BMP)‐9 and 10 have been implicated in tumor angiogenesis. However, previous stud...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Sci
Auteurs principaux: Akatsu, Yuichi, Yoshimatsu, Yasuhiro, Tomizawa, Taishi, Takahashi, Kazuki, Katsura, Akihiro, Miyazono, Kohei, Watabe, Tetsuro
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2017
Sujets:
Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5276835/
https://ncbi.nlm.nih.gov/pubmed/28133920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13103
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires